Clinical trials: Solid Tumors, completed
Solid Tumor
Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
This is planned to be a 5-part dose-escalation study to determine the safety and tolerability of MK-4166 monotherapy and MK-4166 plus pembrolizumab combination therapy, and to establish the maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT02132754
- Testing
- MK-4166, Pembrolizumab
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid Tumors
The study involves the use of three different dosing regimens of AMG 706 in patients with advanced solid tumors to see how the drug affects the gallbladder size and function.
- Trial name
- NCT00448786
- Testing
- AMG 706
- Volunteers
- 49 people
- Sponsor
- Amgen
Solid Tumors
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
This study designed as a multicenter, open label, two-step study to determine the optimum dose, pharmacokinetics, and the safety of RS-0139 in patients with a recurrent, locally advanced or metastatic solid tumors.
- Trial name
- NCT04261413
- Testing
- RS-0139
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 positron emission tomography, may help find and diagnose cancer. It is not yet known whether standard diagnostic procedures are more effective when given with or…
- Trial name
- MVTEP (NCT00964275)
- Testing
- diagnostic procedure, fludeoxyglucose F 18
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Brest
Solid Cancers
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
This is a Phase I, first-in-human, open label, dose-escalation study of MINT1526A administered alone and in combination with bevacizumab by IV infusion every 3 weeks to patients with advanced solid tumors for whom standard…
- Trial name
- NCT01139723
- Testing
- MINT1526A, bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Genentech, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
T138067 Sodium in Treating Patients With Advanced Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of T138067 sodium in treating patients with advanced…
- Trial name
- NCT00003359
- Testing
- batabulin sodium
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignancies
Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.
- Trial name
- NCT00448396
- Testing
- Patupilone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Neoplasms
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with…
- Trial name
- NCT00220649
- Testing
- gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Advanced Solid Tumors, Neoplasms
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer
- Trial name
- NCT00879684
- Testing
- CVX-060
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of oral administration of irinotecan in adult patients. Oral irinotecan will be administered as monotherapy in a dose escalation trial to establish the Maximal…
- Trial name
- NCT03295084
- Testing
- Irinotecan, Capecitabine
- Where
- Denmark
- Volunteers
- 39 people
- Sponsor
- Dorte Nielsen
Hematopoietic and Lymphoid System Neoplasm, Lymphedema
Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study
This clinical trial studies how well new adhesive-based sensors that stick to the skin (transcutaneous) work in detecting cancer-related long-term arm swelling (lymphedema).
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Lymphedema, Malignant Solid Neoplasm
- Trial name
- NCT06305884
- Testing
- Bioelectric Impedance Analysis, Exercise, Photoplethysmography
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Solid Tumors
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a…
- Trial name
- NCT00635284
- Testing
- ABI-009
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celgene
NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
This is a Phase I, open-label, dose escalation study of LNP3794 (BI3011441) in subjects with NRAS/KRAS mutated advanced or metastatic refractory solid tumors.
- Trial name
- NCT05187858
- Testing
- LNP3794
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 15 people
- Sponsor
- Lupin Ltd.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoporosis
Longitudinal Study of Bone Mineral Density in Survivors of Solid Pediatric Cancers
Specific subgroups of children who survive treatment for childhood malignancies have been shown to develop relative osteopenia following chemotherapy and are felt to be at risk for developing osteoporosis later in life due to…
- Trial name
- NCT00615485
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- State University of New York - Upstate Medical University
Advanced Solid Tumors, Cancer
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for…
- Conditions
- Advanced Solid Tumors, Cancer, Hematologic Malignancies
- Trial name
- NCT03082209
- Testing
- ABBV-621, Venetoclax, Bevacizumab
- Where
- 19 sites in United States, Japan and 2 more
- Volunteers
- 153 people
- Sponsor
- AbbVie
Cancer, Oncology
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.
- Conditions
- Cancer, Oncology, Tumors, Advanced Malignancy
- Trial name
- NCT00813384
- Testing
- AMG 208
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Amgen
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
Solid Tumors
Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle
Primary Objective 1. To develop a pharmacokinetic-pharmacodynamic (PD) model for optimisation of docetaxel dosing Secondary Objectives 1. To establish an exposure-toxicity (neutropenia) relationship for docetaxel 2.
- Trial name
- NCT00703378
- Testing
- Docetaxel (Taxotere®)
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- National University Hospital, Singapore
Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction
The aim of this study is to evaluate the impact of concomitant main pancreatic duct exposure, repair, or reconstruction during minimally invasive pancreatic tumor enucleation on long-term patient prognosis and quality of life.
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor, Solid Pseudopapillary Tumor of the Pancreas
- Trial name
- NCT06024343
- Testing
- MPD Exposure, Repair or Reconstruction
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.